JL 17001
Alternative Names: JL-17001Latest Information Update: 10 Jul 2023
At a glance
- Originator JECHO Biopharmaceuticals
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 10 Jul 2023 Early research in Solid tumours in China (Parenteral) before July 2023 (JECHO Biopharmaceuticals pipeline, July 2023)